Association of BRAF p.Val600Glu and KRAS Mutations with Clinicopathologic Characteristics Among Colorectal Cancer Patients in a Tertiary Hospital in West Java, Indonesia
No Thumbnail Available
Date
2023-02-20
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Background: The colorectal cancer (CRC) remains a major burden in cancer worldwide, ranking third and second in incidence and mortality respectively. Detection of biomarkers including BRAF p.Val600Glu and KRAS mutations can help in predicting prognosis and response to therapy in CRC. This study aims to evaluate frequency of BRAF p.Val600Glu and KRAS mutations among Indonesian patients and their associations with patients clinicopathologic characteristics.
Methods: 53 CRC samples were collected from January to September 2022 in the Department of Surgery, Dr. Hasan Sadikin General Hospital, Bandung, Indonesia. BRAF p.Val600Glu and KRAS mutations were analyzed using PCR followed by Sanger sequencing. Associations between BRAF p.Val600Glu and KRAS mutations were evaluated using Pearson`s chi-squared test.
Result: None of the samples were positive BRAF V600E mutation. KRAS mutations were detected in 52.8% patients (n=28), of which 3.6% were p.Gly12Ser (n=1), 32.1% were Gly12Asp (n=9), 7.1% were p.Gly13Asp (n=2), 3.6% were p.Gln61His (n=1), 3.6% were p.Asp126His (n=1), 3.6% were p.Lys169Glu (n=1), and polymorphism of p.Asp73= were detected in 57.1% of the samples (n=16). KRAS mutation status was not associated with age of onset, sex, tumor location, tumor histology, and , family history.
Conclusion: BRAF p.Val600Glu mutations were not observed in this study, while KRAS mutations were present in high frequency. KRAS mutations status do not associate with age of onset, sex, tumor location, tumor histology, and family history.
Description
Keywords
BRAF, V600E, KRAS